1	3	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Discussion	_	_	NN	_	_	_	_	_


1	Kounis	_	_	NNP	_	_	_	_	_
2	syndrome	_	_	NN	_	_	_	_	_
3	is	_	_	VBZ	_	_	_	_	_
4	defined	_	_	VBN	_	_	_	_	_
5	as	_	_	IN	_	_	_	_	_
6	acute	_	_	JJ	_	_	_	_	_
7	coronary	_	_	JJ	_	_	_	_	_
8	syndromes	_	_	NNS	_	_	_	_	_
9	(	_	_	-LRB-	_	_	_	_	_
10	ACS	_	_	NN	_	_	_	_	_
11	)	_	_	-RRB-	_	_	_	_	_
12	induced	_	_	VBN	_	_	_	_	_
13	by	_	_	IN	_	_	_	_	_
14	hypersensitivity	_	_	NN	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	anaphylactic	_	_	JJ	_	_	_	_	_
17	reaction	_	_	NN	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	Several	_	_	JJ	_	_	_	_	_
2	causes	_	_	NNS	_	_	_	_	_
3	are	_	_	VBP	_	_	_	_	_
4	reported	_	_	VBN	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	induce	_	_	VB	_	_	_	_	_
7	Kounis	_	_	NNP	_	_	_	_	_
8	syndrome	_	_	NN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	such	_	_	JJ	_	_	_	_	_
11	as	_	_	IN	_	_	_	_	_
12	medicines	_	_	NNS	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	environmental	_	_	JJ	_	_	_	_	_
15	exposures	_	_	NNS	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	bee	_	_	NN	_	_	_	_	_
18	stings	_	_	NNS	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	asthma	_	_	NN	_	_	_	_	_
22	(	_	_	-LRB-	_	_	_	_	_
23	Table	_	_	NN	_	_	_	_	_
24	2	_	_	CD	_	_	_	_	_
25	)	_	_	-RRB-	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	Ayhan	_	_	NNP	_	_	_	_	_
2	Akoz	_	_	NNP	_	_	_	_	_
3	et	_	_	NNP	_	_	_	_	_
4	al.	_	_	FW	_	_	_	_	_
5	conducted	_	_	VBD	_	_	_	_	_
6	a	_	_	DT	_	_	_	_	_
7	prospective	_	_	JJ	_	_	_	_	_
8	study	_	_	NN	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	found	_	_	VBD	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	incidence	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	Kounis	_	_	NNP	_	_	_	_	_
15	syndrome	_	_	NN	_	_	_	_	_
16	in	_	_	IN	_	_	_	_	_
17	all	_	_	DT	_	_	_	_	_
18	admissions	_	_	NNS	_	_	_	_	_
19	to	_	_	TO	_	_	_	_	_
20	be	_	_	VB	_	_	_	_	_
21	19.4/100,000	_	_	CD	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	most	_	_	RBS	_	_	_	_	_
3	common	_	_	JJ	_	_	_	_	_
4	etiology	_	_	NN	_	_	_	_	_
5	reported	_	_	VBD	_	_	_	_	_
6	was	_	_	VBD	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	use	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	medications	_	_	NNS	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	accounting	_	_	VBG	_	_	_	_	_
13	for	_	_	IN	_	_	_	_	_
14	about	_	_	RB	_	_	_	_	_
15	81	_	_	CD	_	_	_	_	_
16	%	_	_	NN	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	current	_	_	JJ	_	_	_	_	_
4	concept	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	three	_	_	CD	_	_	_	_	_
7	variants	_	_	NNS	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	Kounis	_	_	NNP	_	_	_	_	_
10	syndrome	_	_	NN	_	_	_	_	_
11	have	_	_	VBP	_	_	_	_	_
12	been	_	_	VBN	_	_	_	_	_
13	described	_	_	VBN	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	Type	_	_	NN	_	_	_	_	_
2	I	_	_	PRP	_	_	_	_	_
3	variant	_	_	NN	_	_	_	_	_
4	is	_	_	VBZ	_	_	_	_	_
5	characterized	_	_	VBN	_	_	_	_	_
6	by	_	_	IN	_	_	_	_	_
7	allergy-related	_	_	JJ	_	_	_	_	_
8	coronary	_	_	JJ	_	_	_	_	_
9	spasm	_	_	NN	_	_	_	_	_
10	without	_	_	IN	_	_	_	_	_
11	coronary	_	_	JJ	_	_	_	_	_
12	lesions	_	_	NNS	_	_	_	_	_
13	or	_	_	CC	_	_	_	_	_
14	risk	_	_	NN	_	_	_	_	_
15	factors	_	_	NNS	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	Patients	_	_	NNS	_	_	_	_	_
2	with	_	_	IN	_	_	_	_	_
3	type	_	_	NN	_	_	_	_	_
4	I	_	_	PRP	_	_	_	_	_
5	Kounis	_	_	NNP	_	_	_	_	_
6	syndrome	_	_	NN	_	_	_	_	_
7	present	_	_	VBP	_	_	_	_	_
8	electrocardiographic	_	_	JJ	_	_	_	_	_
9	change	_	_	NN	_	_	_	_	_
10	with	_	_	IN	_	_	_	_	_
11	or	_	_	CC	_	_	_	_	_
12	without	_	_	IN	_	_	_	_	_
13	cardiac	_	_	JJ	_	_	_	_	_
14	enzymes	_	_	NNS	_	_	_	_	_
15	elevation	_	_	NN	_	_	_	_	_
16	due	_	_	JJ	_	_	_	_	_
17	to	_	_	TO	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	acute	_	_	JJ	_	_	_	_	_
20	release	_	_	NN	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	inflammatory	_	_	JJ	_	_	_	_	_
23	mediators	_	_	NNS	_	_	_	_	_
24	inducing	_	_	VBG	_	_	_	_	_
25	coronary	_	_	JJ	_	_	_	_	_
26	spasm	_	_	NN	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	type	_	_	NN	_	_	_	_	_
3	II	_	_	NN	_	_	_	_	_
4	variant	_	_	NN	_	_	_	_	_
5	includes	_	_	VBZ	_	_	_	_	_
6	pre-existing	_	_	JJ	_	_	_	_	_
7	atheromatous	_	_	JJ	_	_	_	_	_
8	disease	_	_	NN	_	_	_	_	_
9	.	_	_	.	_	_	_	_	_


1	An	_	_	DT	_	_	_	_	_
2	acute	_	_	JJ	_	_	_	_	_
3	allergic	_	_	JJ	_	_	_	_	_
4	reaction	_	_	NN	_	_	_	_	_
5	leading	_	_	VBG	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	release	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	inflammatory	_	_	JJ	_	_	_	_	_
11	mediators	_	_	NNS	_	_	_	_	_
12	induces	_	_	VBZ	_	_	_	_	_
13	plaque	_	_	NN	_	_	_	_	_
14	erosion	_	_	NN	_	_	_	_	_
15	or	_	_	CC	_	_	_	_	_
16	rupture	_	_	NN	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	which	_	_	WDT	_	_	_	_	_
19	causes	_	_	VBZ	_	_	_	_	_
20	acute	_	_	JJ	_	_	_	_	_
21	myocardial	_	_	JJ	_	_	_	_	_
22	infarction	_	_	NN	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	Type	_	_	NN	_	_	_	_	_
2	III	_	_	CD	_	_	_	_	_
3	has	_	_	VBZ	_	_	_	_	_
4	been	_	_	VBN	_	_	_	_	_
5	defined	_	_	VBN	_	_	_	_	_
6	in	_	_	IN	_	_	_	_	_
7	patients	_	_	NNS	_	_	_	_	_
8	with	_	_	IN	_	_	_	_	_
9	pre-existing	_	_	JJ	_	_	_	_	_
10	coronary	_	_	JJ	_	_	_	_	_
11	disease	_	_	NN	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	coronary	_	_	JJ	_	_	_	_	_
14	artery	_	_	NN	_	_	_	_	_
15	stent	_	_	NN	_	_	_	_	_
16	thrombosis	_	_	NN	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	Jack	_	_	NNP	_	_	_	_	_
4	P.	_	_	NNP	_	_	_	_	_
5	Chen	_	_	NNP	_	_	_	_	_
6	et	_	_	FW	_	_	_	_	_
7	al.	_	_	FW	_	_	_	_	_
8	study	_	_	NN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	pathology	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	drug-eluting	_	_	JJ	_	_	_	_	_
14	stent	_	_	NN	_	_	_	_	_
15	(	_	_	-LRB-	_	_	_	_	_
16	DES	_	_	NNP	_	_	_	_	_
17	)	_	_	-RRB-	_	_	_	_	_
18	thrombosis	_	_	NN	_	_	_	_	_
19	in	_	_	IN	_	_	_	_	_
20	these	_	_	DT	_	_	_	_	_
21	patients	_	_	NNS	_	_	_	_	_
22	presented	_	_	VBN	_	_	_	_	_
23	with	_	_	IN	_	_	_	_	_
24	eosinophils	_	_	NNS	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	mast	_	_	NN	_	_	_	_	_
27	cell	_	_	NN	_	_	_	_	_
28	infiltration	_	_	NN	_	_	_	_	_
29	in	_	_	IN	_	_	_	_	_
30	Giemsa	_	_	NNP	_	_	_	_	_
31	and	_	_	CC	_	_	_	_	_
32	hematoxylin	_	_	NN	_	_	_	_	_
33	–	_	_	:	_	_	_	_	_
34	eosin	_	_	NN	_	_	_	_	_
35	staining	_	_	NN	_	_	_	_	_
36	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	Stéphane	_	_	NNP	_	_	_	_	_
4	Cook	_	_	NNP	_	_	_	_	_
5	et	_	_	FW	_	_	_	_	_
6	al.	_	_	FW	_	_	_	_	_
7	study	_	_	NN	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	association	_	_	NN	_	_	_	_	_
11	with	_	_	IN	_	_	_	_	_
12	late	_	_	JJ	_	_	_	_	_
13	DES	_	_	NNP	_	_	_	_	_
14	thrombosis	_	_	NN	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	local	_	_	JJ	_	_	_	_	_
17	inflammation	_	_	NN	_	_	_	_	_
18	in	_	_	IN	_	_	_	_	_
19	histopathology	_	_	NN	_	_	_	_	_
20	was	_	_	VBD	_	_	_	_	_
21	reported	_	_	VBN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	intravascular	_	_	JJ	_	_	_	_	_
3	ultrasound	_	_	NN	_	_	_	_	_
4	analysis	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	vessel	_	_	NN	_	_	_	_	_
7	remodeling	_	_	NN	_	_	_	_	_
8	was	_	_	VBD	_	_	_	_	_
9	also	_	_	RB	_	_	_	_	_
10	confirmed	_	_	VBN	_	_	_	_	_
11	.	_	_	.	_	_	_	_	_


1	Very	_	_	RB	_	_	_	_	_
2	late	_	_	JJ	_	_	_	_	_
3	stent	_	_	NN	_	_	_	_	_
4	thrombosis	_	_	NN	_	_	_	_	_
5	is	_	_	VBZ	_	_	_	_	_
6	recognized	_	_	VBN	_	_	_	_	_
7	as	_	_	IN	_	_	_	_	_
8	a	_	_	DT	_	_	_	_	_
9	feature	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	Kounis	_	_	NNP	_	_	_	_	_
12	syndrome	_	_	NN	_	_	_	_	_
13	(	_	_	-LRB-	_	_	_	_	_
14	Figure	_	_	NN	_	_	_	_	_
15	5	_	_	CD	_	_	_	_	_
16	)	_	_	-RRB-	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	detail	_	_	NN	_	_	_	_	_
3	pathophysiological	_	_	JJ	_	_	_	_	_
4	mechanisms	_	_	NNS	_	_	_	_	_
5	remain	_	_	VBP	_	_	_	_	_
6	elusive	_	_	JJ	_	_	_	_	_
7	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	current	_	_	JJ	_	_	_	_	_
4	concept	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	Kounis	_	_	NNP	_	_	_	_	_
7	syndrome	_	_	NN	_	_	_	_	_
8	is	_	_	VBZ	_	_	_	_	_
9	related	_	_	VBN	_	_	_	_	_
10	to	_	_	TO	_	_	_	_	_
11	inflammatory	_	_	JJ	_	_	_	_	_
12	cell	_	_	NN	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	mast	_	_	NN	_	_	_	_	_
15	cell-associated	_	_	JJ	_	_	_	_	_
16	disorders	_	_	NNS	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	Local	_	_	JJ	_	_	_	_	_
2	inflammatory	_	_	JJ	_	_	_	_	_
3	cell	_	_	NN	_	_	_	_	_
4	interactions	_	_	NNS	_	_	_	_	_
5	induce	_	_	VBP	_	_	_	_	_
6	hypersensitivity	_	_	NN	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	anaphylactic	_	_	JJ	_	_	_	_	_
9	results	_	_	NNS	_	_	_	_	_
10	by	_	_	IN	_	_	_	_	_
11	releasing	_	_	VBG	_	_	_	_	_
12	inflammatory	_	_	JJ	_	_	_	_	_
13	mediators	_	_	NNS	_	_	_	_	_
14	after	_	_	IN	_	_	_	_	_
15	activation	_	_	NN	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	Nicholas	_	_	NNP	_	_	_	_	_
4	G.	_	_	NNP	_	_	_	_	_
5	Kounis	_	_	NNP	_	_	_	_	_
6	et	_	_	FW	_	_	_	_	_
7	al.	_	_	FW	_	_	_	_	_
8	summary	_	_	NN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	Kounis	_	_	NNP	_	_	_	_	_
11	syndrome	_	_	NN	_	_	_	_	_
12	is	_	_	VBZ	_	_	_	_	_
13	a	_	_	DT	_	_	_	_	_
14	complex	_	_	JJ	_	_	_	_	_
15	multisystem	_	_	NN	_	_	_	_	_
16	disease	_	_	NN	_	_	_	_	_
17	accompanied	_	_	VBN	_	_	_	_	_
18	by	_	_	IN	_	_	_	_	_
19	allergy	_	_	NN	_	_	_	_	_
20	–	_	_	:	_	_	_	_	_
21	hypersensitivity	_	_	NN	_	_	_	_	_
22	–	_	_	:	_	_	_	_	_
23	anaphylaxis	_	_	NN	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	During	_	_	IN	_	_	_	_	_
2	hypersensitivity	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	mast	_	_	NN	_	_	_	_	_
6	cells	_	_	NNS	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	lymphocytes	_	_	NNS	_	_	_	_	_
9	release	_	_	VBP	_	_	_	_	_
10	inflammatory	_	_	JJ	_	_	_	_	_
11	mediators	_	_	NNS	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	promoting	_	_	VBG	_	_	_	_	_
14	an	_	_	DT	_	_	_	_	_
15	allergic	_	_	JJ	_	_	_	_	_
16	reaction	_	_	NN	_	_	_	_	_
17	via	_	_	IN	_	_	_	_	_
18	a	_	_	DT	_	_	_	_	_
19	high	_	_	JJ	_	_	_	_	_
20	serum	_	_	NN	_	_	_	_	_
21	level	_	_	NN	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	histamine	_	_	NN	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	proteases	_	_	NNS	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	arachidonic	_	_	JJ	_	_	_	_	_
28	acid	_	_	NN	_	_	_	_	_
29	products	_	_	NNS	_	_	_	_	_
30	,	_	_	,	_	_	_	_	_
31	and	_	_	CC	_	_	_	_	_
32	chemokines	_	_	NNS	_	_	_	_	_
33	.	_	_	.	_	_	_	_	_


1	These	_	_	DT	_	_	_	_	_
2	factors	_	_	NNS	_	_	_	_	_
3	cause	_	_	VBP	_	_	_	_	_
4	platelet	_	_	NN	_	_	_	_	_
5	aggregating	_	_	NN	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	tissue	_	_	NN	_	_	_	_	_
8	factor	_	_	NN	_	_	_	_	_
9	expression	_	_	NN	_	_	_	_	_
10	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	proteases	_	_	NNS	_	_	_	_	_
3	also	_	_	RB	_	_	_	_	_
4	induce	_	_	VBP	_	_	_	_	_
5	plaque	_	_	NN	_	_	_	_	_
6	erosion	_	_	NN	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	rupture	_	_	NN	_	_	_	_	_
9	by	_	_	IN	_	_	_	_	_
10	activating	_	_	VBG	_	_	_	_	_
11	matrix	_	_	NN	_	_	_	_	_
12	metalloproteinase	_	_	NN	_	_	_	_	_
13	(	_	_	-LRB-	_	_	_	_	_
14	MMP	_	_	NN	_	_	_	_	_
15	)	_	_	-RRB-	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	downstream	_	_	JJ	_	_	_	_	_
3	mediators	_	_	NNS	_	_	_	_	_
4	induce	_	_	VBP	_	_	_	_	_
5	vasoconstriction	_	_	NN	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	worsen	_	_	VB	_	_	_	_	_
8	coronary	_	_	JJ	_	_	_	_	_
9	vasospasm	_	_	NN	_	_	_	_	_
10	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	diagnosis	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	Kounis	_	_	NNP	_	_	_	_	_
5	syndrome	_	_	NN	_	_	_	_	_
6	is	_	_	VBZ	_	_	_	_	_
7	based	_	_	VBN	_	_	_	_	_
8	on	_	_	IN	_	_	_	_	_
9	clinical	_	_	JJ	_	_	_	_	_
10	symptoms	_	_	NNS	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	cardiac	_	_	JJ	_	_	_	_	_
13	surveys	_	_	NNS	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	including	_	_	VBG	_	_	_	_	_
16	cardiac	_	_	JJ	_	_	_	_	_
17	enzyme	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	electrocardiographic	_	_	JJ	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	echocardiographic	_	_	JJ	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	angiography	_	_	NN	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	serum	_	_	NN	_	_	_	_	_
3	level	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	tryptase	_	_	NN	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	histamine	_	_	NN	_	_	_	_	_
8	can	_	_	MD	_	_	_	_	_
9	provide	_	_	VB	_	_	_	_	_
10	more	_	_	JJR	_	_	_	_	_
11	information	_	_	NN	_	_	_	_	_
12	about	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	allergic	_	_	JJ	_	_	_	_	_
15	reaction	_	_	NN	_	_	_	_	_
16	(	_	_	-LRB-	_	_	_	_	_
17	Figure	_	_	NN	_	_	_	_	_
18	5	_	_	CD	_	_	_	_	_
19	)	_	_	-RRB-	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	Tajda	_	_	NNP	_	_	_	_	_
2	Keber	_	_	NNP	_	_	_	_	_
3	et	_	_	FW	_	_	_	_	_
4	al.	_	_	FW	_	_	_	_	_


1	suggested	_	_	VBD	_	_	_	_	_
2	measuring	_	_	VBG	_	_	_	_	_
3	cardiac	_	_	JJ	_	_	_	_	_
4	enzymes	_	_	NNS	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	acute	_	_	JJ	_	_	_	_	_
7	allergic	_	_	JJ	_	_	_	_	_
8	reaction	_	_	NN	_	_	_	_	_
9	patients	_	_	NNS	_	_	_	_	_
10	as	_	_	IN	_	_	_	_	_
11	necessary	_	_	JJ	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	diagnose	_	_	VB	_	_	_	_	_
14	Kounis	_	_	NNP	_	_	_	_	_
15	syndrome	_	_	NN	_	_	_	_	_
16	promptly	_	_	RB	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	manage	_	_	VB	_	_	_	_	_
19	cardiac	_	_	JJ	_	_	_	_	_
20	injury	_	_	NN	_	_	_	_	_
21	early	_	_	RB	_	_	_	_	_
22	and	_	_	CC	_	_	_	_	_
23	appropriately	_	_	RB	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	Echocardiography	_	_	NN	_	_	_	_	_
2	and	_	_	CC	_	_	_	_	_
3	coronary	_	_	JJ	_	_	_	_	_
4	angiography	_	_	NN	_	_	_	_	_
5	can	_	_	MD	_	_	_	_	_
6	provide	_	_	VB	_	_	_	_	_
7	detailed	_	_	JJ	_	_	_	_	_
8	information	_	_	NN	_	_	_	_	_
9	to	_	_	TO	_	_	_	_	_
10	rule	_	_	VB	_	_	_	_	_
11	out	_	_	RP	_	_	_	_	_
12	takotsubo	_	_	NN	_	_	_	_	_
13	cardiomyopathy	_	_	NN	_	_	_	_	_
14	or	_	_	CC	_	_	_	_	_
15	other	_	_	JJ	_	_	_	_	_
16	cardiac	_	_	JJ	_	_	_	_	_
17	disorders	_	_	NNS	_	_	_	_	_
18	in	_	_	IN	_	_	_	_	_
19	cardiac	_	_	JJ	_	_	_	_	_
20	wall	_	_	NN	_	_	_	_	_
21	motion	_	_	NN	_	_	_	_	_
22	abnormalities	_	_	NNS	_	_	_	_	_
23	patients	_	_	NNS	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_
25	Keita	_	_	NNP	_	_	_	_	_
26	Goto	_	_	NNP	_	_	_	_	_
27	et	_	_	FW	_	_	_	_	_
28	al.	_	_	FW	_	_	_	_	_
29	reported	_	_	VBD	_	_	_	_	_
30	that	_	_	IN	_	_	_	_	_
31	thallium-201	_	_	NN	_	_	_	_	_
32	(	_	_	-LRB-	_	_	_	_	_
33	Tl	_	_	NN	_	_	_	_	_
34	)	_	_	-RRB-	_	_	_	_	_
35	single-photon	_	_	NN	_	_	_	_	_
36	emission	_	_	NN	_	_	_	_	_
37	CT	_	_	NN	_	_	_	_	_
38	(	_	_	-LRB-	_	_	_	_	_
39	SPECT	_	_	NN	_	_	_	_	_
40	)	_	_	-RRB-	_	_	_	_	_
41	and	_	_	CC	_	_	_	_	_
42	125I-15-(p-iodophenyl)-3-(R	_	_	CD	_	_	_	_	_
43	,	_	_	,	_	_	_	_	_
44	S)-methylpentadecanoic	_	_	JJ	_	_	_	_	_
45	acid	_	_	NN	_	_	_	_	_
46	(	_	_	-LRB-	_	_	_	_	_
47	BMIPP	_	_	NNP	_	_	_	_	_
48	)	_	_	-RRB-	_	_	_	_	_
49	SPECT	_	_	NNP	_	_	_	_	_
50	were	_	_	VBD	_	_	_	_	_
51	conducted	_	_	VBN	_	_	_	_	_
52	in	_	_	IN	_	_	_	_	_
53	a	_	_	DT	_	_	_	_	_
54	post-Kounis	_	_	JJ	_	_	_	_	_
55	syndrome	_	_	NN	_	_	_	_	_
56	patient	_	_	NN	_	_	_	_	_
57	,	_	_	,	_	_	_	_	_
58	and	_	_	CC	_	_	_	_	_
59	they	_	_	PRP	_	_	_	_	_
60	revealed	_	_	VBD	_	_	_	_	_
61	a	_	_	DT	_	_	_	_	_
62	local	_	_	JJ	_	_	_	_	_
63	perfusion	_	_	NN	_	_	_	_	_
64	defect	_	_	NN	_	_	_	_	_
65	with	_	_	IN	_	_	_	_	_
66	decreased	_	_	VBN	_	_	_	_	_
67	BMIPP	_	_	NNP	_	_	_	_	_
68	uptake	_	_	NN	_	_	_	_	_
69	.	_	_	.	_	_	_	_	_


1	Aylin	_	_	NNP	_	_	_	_	_
2	Okur	_	_	NNP	_	_	_	_	_
3	et	_	_	FW	_	_	_	_	_
4	al.	_	_	FW	_	_	_	_	_
5	included	_	_	VBD	_	_	_	_	_
6	26	_	_	CD	_	_	_	_	_
7	patients	_	_	NNS	_	_	_	_	_
8	with	_	_	IN	_	_	_	_	_
9	known	_	_	VBN	_	_	_	_	_
10	or	_	_	CC	_	_	_	_	_
11	suspected	_	_	VBN	_	_	_	_	_
12	Kounis	_	_	NNP	_	_	_	_	_
13	syndrome	_	_	NN	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	conducted	_	_	VBD	_	_	_	_	_
16	contrast-enhanced	_	_	JJ	_	_	_	_	_
17	magnetic	_	_	JJ	_	_	_	_	_
18	resonance	_	_	NN	_	_	_	_	_
19	imaging	_	_	NN	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	results	_	_	NNS	_	_	_	_	_
3	revealed	_	_	VBD	_	_	_	_	_
4	an	_	_	DT	_	_	_	_	_
5	early-phase	_	_	JJ	_	_	_	_	_
6	subendocardial	_	_	JJ	_	_	_	_	_
7	contrast	_	_	NN	_	_	_	_	_
8	defect	_	_	NN	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	local	_	_	JJ	_	_	_	_	_
11	edema	_	_	NN	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	lesion	_	_	NN	_	_	_	_	_
14	areas	_	_	NNS	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	T2-weighted	_	_	JJ	_	_	_	_	_
17	images	_	_	NNS	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	These	_	_	DT	_	_	_	_	_
2	newer	_	_	JJR	_	_	_	_	_
3	images	_	_	NNS	_	_	_	_	_
4	provide	_	_	VBP	_	_	_	_	_
5	a	_	_	DT	_	_	_	_	_
6	reliable	_	_	JJ	_	_	_	_	_
7	study	_	_	NN	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	assess	_	_	VB	_	_	_	_	_
10	cardiac	_	_	JJ	_	_	_	_	_
11	injury	_	_	NN	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	Kounis	_	_	NNP	_	_	_	_	_
14	syndrome	_	_	NN	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	Compared	_	_	VBN	_	_	_	_	_
2	to	_	_	TO	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	majority	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	ACS	_	_	NNP	_	_	_	_	_
7	subjects	_	_	NNS	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	therapeutic	_	_	JJ	_	_	_	_	_
11	strategy	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	Kounis	_	_	NNP	_	_	_	_	_
14	syndrome	_	_	NN	_	_	_	_	_
15	should	_	_	MD	_	_	_	_	_
16	focus	_	_	VB	_	_	_	_	_
17	on	_	_	IN	_	_	_	_	_
18	both	_	_	CC	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	cardiac	_	_	JJ	_	_	_	_	_
21	injury	_	_	NN	_	_	_	_	_
22	and	_	_	CC	_	_	_	_	_
23	allergic	_	_	JJ	_	_	_	_	_
24	reaction	_	_	NN	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	Sometimes	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	two	_	_	CD	_	_	_	_	_
5	different	_	_	JJ	_	_	_	_	_
6	conditions	_	_	NNS	_	_	_	_	_
7	may	_	_	MD	_	_	_	_	_
8	require	_	_	VB	_	_	_	_	_
9	opposing	_	_	VBG	_	_	_	_	_
10	treatments	_	_	NNS	_	_	_	_	_
11	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	current	_	_	JJ	_	_	_	_	_
4	concept	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	administration	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	medicine	_	_	NN	_	_	_	_	_
10	should	_	_	MD	_	_	_	_	_
11	avoid	_	_	VB	_	_	_	_	_
12	promoting	_	_	VBG	_	_	_	_	_
13	an	_	_	DT	_	_	_	_	_
14	allergy	_	_	NN	_	_	_	_	_
15	reaction	_	_	NN	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	aggravating	_	_	VBG	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	cardiac	_	_	JJ	_	_	_	_	_
20	injury	_	_	NN	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	Intravenous	_	_	JJ	_	_	_	_	_
2	corticosteroids	_	_	NNS	_	_	_	_	_
3	(	_	_	-LRB-	_	_	_	_	_
4	hydrocortisone	_	_	NN	_	_	_	_	_
5	:	_	_	:	_	_	_	_	_
6	1	_	_	CD	_	_	_	_	_
7	–	_	_	TO	_	_	_	_	_
8	2	_	_	CD	_	_	_	_	_
9	mg/kg/day	_	_	NN	_	_	_	_	_
10	)	_	_	-RRB-	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	antihistamine	_	_	NN	_	_	_	_	_
13	agents	_	_	NNS	_	_	_	_	_
14	(	_	_	-LRB-	_	_	_	_	_
15	diphenhydramine	_	_	NN	_	_	_	_	_
16	:	_	_	:	_	_	_	_	_
17	1	_	_	CD	_	_	_	_	_
18	–	_	_	TO	_	_	_	_	_
19	2	_	_	CD	_	_	_	_	_
20	mg/kg	_	_	NN	_	_	_	_	_
21	)	_	_	-RRB-	_	_	_	_	_
22	are	_	_	VBP	_	_	_	_	_
23	useful	_	_	JJ	_	_	_	_	_
24	to	_	_	TO	_	_	_	_	_
25	control	_	_	VB	_	_	_	_	_
26	the	_	_	DT	_	_	_	_	_
27	allergic	_	_	JJ	_	_	_	_	_
28	reaction	_	_	NN	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	Aspirin	_	_	NN	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	however	_	_	RB	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	potentially	_	_	RB	_	_	_	_	_
7	detrimental	_	_	JJ	_	_	_	_	_
8	because	_	_	IN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	cyclooxygenase	_	_	NN	_	_	_	_	_
11	inhibition	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	promoting	_	_	VBG	_	_	_	_	_
14	arachidonic	_	_	JJ	_	_	_	_	_
15	acid	_	_	NN	_	_	_	_	_
16	release	_	_	NN	_	_	_	_	_
17	into	_	_	IN	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	leukotriene	_	_	NN	_	_	_	_	_
20	pathway	_	_	NN	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	Calcium	_	_	NN	_	_	_	_	_
2	channel	_	_	NN	_	_	_	_	_
3	blockers	_	_	NNS	_	_	_	_	_
4	and	_	_	CC	_	_	_	_	_
5	nitrates	_	_	NNS	_	_	_	_	_
6	can	_	_	MD	_	_	_	_	_
7	relieve	_	_	VB	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	vasospasm	_	_	NN	_	_	_	_	_
10	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	hemodynamically	_	_	RB	_	_	_	_	_
3	unstable	_	_	JJ	_	_	_	_	_
4	patients	_	_	NNS	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	nitrates	_	_	NNS	_	_	_	_	_
7	may	_	_	MD	_	_	_	_	_
8	not	_	_	RB	_	_	_	_	_
9	be	_	_	VB	_	_	_	_	_
10	appropriate	_	_	JJ	_	_	_	_	_
11	due	_	_	JJ	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	their	_	_	PRP$	_	_	_	_	_
14	hypotension	_	_	NN	_	_	_	_	_
15	properties	_	_	NNS	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	Opioids	_	_	NNS	_	_	_	_	_
2	may	_	_	MD	_	_	_	_	_
3	induce	_	_	VB	_	_	_	_	_
4	mast	_	_	NN	_	_	_	_	_
5	cell	_	_	NN	_	_	_	_	_
6	degeneration	_	_	NN	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	which	_	_	WDT	_	_	_	_	_
9	may	_	_	MD	_	_	_	_	_
10	worsen	_	_	VB	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	anaphylaxis	_	_	NN	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	Beta-blockers	_	_	NNS	_	_	_	_	_
2	should	_	_	MD	_	_	_	_	_
3	be	_	_	VB	_	_	_	_	_
4	used	_	_	VBN	_	_	_	_	_
5	with	_	_	IN	_	_	_	_	_
6	extreme	_	_	JJ	_	_	_	_	_
7	caution	_	_	NN	_	_	_	_	_
8	because	_	_	IN	_	_	_	_	_
9	they	_	_	PRP	_	_	_	_	_
10	can	_	_	MD	_	_	_	_	_
11	exaggerate	_	_	VB	_	_	_	_	_
12	coronary	_	_	JJ	_	_	_	_	_
13	spasms	_	_	NNS	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	cause	_	_	VB	_	_	_	_	_
16	epinephrine	_	_	NN	_	_	_	_	_
17	to	_	_	TO	_	_	_	_	_
18	be	_	_	VB	_	_	_	_	_
19	ineffective	_	_	JJ	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	Epinephrine	_	_	NNP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	only	_	_	JJ	_	_	_	_	_
5	life-saving	_	_	JJ	_	_	_	_	_
6	drug	_	_	NN	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	event	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	aggravated	_	_	VBN	_	_	_	_	_
12	ischemia	_	_	NN	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	vasospasm	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	arrhythmias	_	_	NNS	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	some	_	_	DT	_	_	_	_	_
3	animal	_	_	NN	_	_	_	_	_
4	studies	_	_	NNS	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	adrenaline	_	_	NN	_	_	_	_	_
7	may	_	_	MD	_	_	_	_	_
8	cause	_	_	VB	_	_	_	_	_
9	LV	_	_	NN	_	_	_	_	_
10	impairment	_	_	NN	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	not	_	_	RB	_	_	_	_	_
13	recovery	_	_	NN	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	established	_	_	VBN	_	_	_	_	_
16	anaphylactic	_	_	JJ	_	_	_	_	_
17	shock	_	_	NN	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	Therefore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	adrenaline	_	_	NN	_	_	_	_	_
4	is	_	_	VBZ	_	_	_	_	_
5	only	_	_	RB	_	_	_	_	_
6	suggested	_	_	VBN	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	high-grade	_	_	JJ	_	_	_	_	_
9	anaphylactic	_	_	JJ	_	_	_	_	_
10	reactions	_	_	NNS	_	_	_	_	_
11	.	_	_	.	_	_	_	_	_


1	Adequate	_	_	JJ	_	_	_	_	_
2	fluids	_	_	NNS	_	_	_	_	_
3	resuscitation	_	_	NN	_	_	_	_	_
4	and	_	_	CC	_	_	_	_	_
5	oxygen	_	_	NN	_	_	_	_	_
6	therapy	_	_	NN	_	_	_	_	_
7	are	_	_	VBP	_	_	_	_	_
8	important	_	_	JJ	_	_	_	_	_
9	supportive	_	_	JJ	_	_	_	_	_
10	treatments	_	_	NNS	_	_	_	_	_
11	for	_	_	IN	_	_	_	_	_
12	Kounis	_	_	NNP	_	_	_	_	_
13	syndrome	_	_	NN	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	Type	_	_	NN	_	_	_	_	_
2	II	_	_	CD	_	_	_	_	_
3	variant	_	_	NN	_	_	_	_	_
4	patients	_	_	NNS	_	_	_	_	_
5	can	_	_	MD	_	_	_	_	_
6	take	_	_	VB	_	_	_	_	_
7	advantage	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	an	_	_	DT	_	_	_	_	_
10	ACS	_	_	NN	_	_	_	_	_
11	protocol	_	_	NN	_	_	_	_	_
12	.	_	_	.	_	_	_	_	_


1	Double	_	_	JJ	_	_	_	_	_
2	antiplatelet	_	_	NN	_	_	_	_	_
3	therapy	_	_	NN	_	_	_	_	_
4	in	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	pharmacological	_	_	JJ	_	_	_	_	_
7	treatment	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	myocardial	_	_	JJ	_	_	_	_	_
10	revascularization	_	_	NN	_	_	_	_	_
11	is	_	_	VBZ	_	_	_	_	_
12	suggested	_	_	VBN	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	including	_	_	VBG	_	_	_	_	_
15	acetylsalicylic	_	_	JJ	_	_	_	_	_
16	acid	_	_	NN	_	_	_	_	_
17	(	_	_	-LRB-	_	_	_	_	_
18	ASA	_	_	NN	_	_	_	_	_
19	)	_	_	-RRB-	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	another	_	_	DT	_	_	_	_	_
22	P2Y12	_	_	NN	_	_	_	_	_
23	receptor	_	_	NN	_	_	_	_	_
24	inhibitor	_	_	NN	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	type	_	_	NN	_	_	_	_	_
4	III	_	_	NN	_	_	_	_	_
5	variant	_	_	NN	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	ACS	_	_	NNP	_	_	_	_	_
9	protocol	_	_	NN	_	_	_	_	_
10	accompanied	_	_	VBN	_	_	_	_	_
11	by	_	_	IN	_	_	_	_	_
12	urgent	_	_	JJ	_	_	_	_	_
13	aspiration	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	intrastent	_	_	NN	_	_	_	_	_
16	thrombus	_	_	NN	_	_	_	_	_
17	is	_	_	VBZ	_	_	_	_	_
18	suggested	_	_	VBN	_	_	_	_	_
19	(	_	_	-LRB-	_	_	_	_	_
20	Figure	_	_	NN	_	_	_	_	_
21	5	_	_	CD	_	_	_	_	_
22	)	_	_	-RRB-	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	Antihistamines	_	_	NNS	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	corticosteroids	_	_	NNS	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	and	_	_	CC	_	_	_	_	_
6	mast	_	_	NN	_	_	_	_	_
7	cell	_	_	NN	_	_	_	_	_
8	stabilizers	_	_	NNS	_	_	_	_	_
9	may	_	_	MD	_	_	_	_	_
10	be	_	_	VB	_	_	_	_	_
11	helpful	_	_	JJ	_	_	_	_	_
12	for	_	_	IN	_	_	_	_	_
13	allergic	_	_	JJ	_	_	_	_	_
14	symptoms	_	_	NNS	_	_	_	_	_
15	after	_	_	IN	_	_	_	_	_
16	stent	_	_	NN	_	_	_	_	_
17	implantation	_	_	NN	_	_	_	_	_
18	or	_	_	CC	_	_	_	_	_
19	revascularization	_	_	NN	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_

